Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Peripheral Artery Disease
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Enrollment
- 713
- Locations
- 4
- Primary Endpoint
- To know the prevalence of PAD in patients with CAD using the automatic device MESI ankle-brachial pressure index (ABPI) MD®
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Patients with lower extremity peripheral artery disease (PAD) are at risk of developing major adverse limb events and have a similar cardiovascular (CV) morbidity and mortality to those with coronary artery disease (CAD) with which is associated in most cases with a more severe prognosis. Because of higher risk conferred by concomitant PAD an early diagnosis is recommended in subjects with CAD. PAD can be diagnosed relatively easily and noninvasively with the ankle-brachial index (ABI) measure. An ABI ≤0.9 is an indicator of the presence of lower extremity PAD, indicating athero-occlusive arterial disease while >1.3/1.4 indicates an incompressible ankle arteries. However, ABI is not routinely applied in the clinical practice. Data on prevalence of PAD are scanty and in patients with stable CAD are lacking. The under-diagnosis of PAD may be a barrier to the use of treatments to improve prognosis. The primary aim of this study is to assess the coexistence of PAD in subjects with stable CAD and to evaluate the management and the prognosis of these patients in primary care at 12-month after the inclusion in the study.
Detailed Description
National, multicentre, observational, prospective study. This study will be carried out with the collaboration with Study Center for Primary Care and with the Italian Society of Angiology and Vascular Medicine (SIAPAV). The eligible patients with stable CAD will be called by General Practitioners (GPs). For all patients who agree to participate in the study and sign the consent, two visits will be done at baseline and after 12 months. At baseline will be collected information on socio-demographic and anthropometric data, blood pressure, heart rate, CV risk factors, medical history, lifestyle habits, PAD stage (for patient with abnormal ABI) and pharmacological therapy. ABI measurement will be done using an automatic simple device. In case of abnormal ABI value, a SIAPAV vascular specialist, at GP's office, will confirm it using the standard manual continuous wave (CW) Doppler. At follow-up visit the following information will be collected the: referral to vascular specialist (if requested, at discretion of the GP), relevant change in pharmacological therapy, major CV events and progression of PAD, limb and coronary artery revascularizations, amputations, major bleeding, and death.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients of both sexes with a diagnosis of stable CAD as follows: acute myocardial infarction or percutaneous coronary revascularization or coronary artery bypass graft surgery occured at least 12 months before entering the study or chronic stable angina.
Exclusion Criteria
- •Mental illness limiting the capacity of self-care or any condition limiting seriously the life expectancy less than 12 months.
Outcomes
Primary Outcomes
To know the prevalence of PAD in patients with CAD using the automatic device MESI ankle-brachial pressure index (ABPI) MD®
Time Frame: 1 day
The prevalence of PAD will be diagnosed measuring the ankle-brachial-index (ABI) determined by dividing the higher systolic pressure measured at the ankle of both legs by the brachial arterial systolic pressure. An ABI value \<=0.9 is an indicator of the presence of PAD indicating athero-occlusive arterial disease while \>1.3/1.4 indicates an incompressible ankle arteries. The ABI measurement will be performed using the automatic device MESI ABPI MD.
Secondary Outcomes
- Clinical History of Heart Failure(1 day)
- To measure the Body mass index (Kg/m2)(1 day)
- Glycemia (mg/dL)(1 day)
- Aspartate aminotransferase (AST) (U/L)(1 day)
- Clinical History of Clinical presentation of lower extremity disease(1 day)
- Clinical History of Transient ischemic attack(1 day)
- Platelet count (x 103μL)(1 day)
- Hematocrit (%)(1 day)
- To measure the Heart rate (bpm)(1 day)
- Clinical History of Limb or foot amputation for arterial vascular disease(1 day)
- Clinical History of Hypertension(1 day)
- The dietary habits(1 day)
- LDL cholesterol (mg/dL)(1 day)
- HDL cholesterol (mg/dL)(1 day)
- Alanine aminotransferase (ALT) (U/L)(1 day)
- Hemoglobin (g/dL)(1 day)
- Marital status(1 day)
- Education Status(1 day)
- To measure the Blood pressure (mmHg)(1 day)
- To measure the Weight (kg)(1 day)
- To measure the Height (cm)(1 day)
- To measure the Ankle Brachial Index (ABI) Value(1 day)
- Clinical History of Limb peripheral artery revascularization(1 day)
- Clinical History of Aortic aneurysm(1 day)
- Clinical History of Carotid artery stenosis(1 day)
- Clinical History of Atrial Fibrillation or Flutter(1 day)
- Clinical History of Chronic Kidney disease(1 day)
- Clinical History of Bleeding(1 day)
- Physical activity(1 day)
- Glycated hemoglobin (only for patients with diabetes mellitus) (%)(1 day)
- Employment status(1 day)
- Clinical History of Dyslipidemia(1 day)
- Clinical History of Stroke(1 day)
- Clinical History of cancer(1 day)
- Total cholesterol (mg/dL)(1 day)
- Triglycerides (mg/dL)(1 day)
- Creatinine (mg/dL)(1 day)
- Red blood cells (x10^3 ml)(1 day)
- White blood cells (x10^3 ml)(1 day)